Christopher Becker has been promoted to vice president of chemistry at SurroMed, and William Leschensky has been promoted to president, intellectual property. Becker joined SurroMed as director of chemistry in 2001, after serving as senior director of proteomics technology at Thermo Electron, and previously, as a staff scientist at SRI. He received his PhD in chemistry at UC Berkeley. Leschensky has been director of intellectual property at SurroMed since 2000, and has also been associate general counsel. Before joining SurroMed, he was an associate at the law firm Fish & Neave. He received his MD from the University of Illinois and a law degree from Harvard Law School.
Alan Carter has been appointed vice president, worldwide sales of BioTrove. Carter comes to the Woburn, Mass., company from Gene Logic, where he was director of business development.
Prior to working at Gene Logic, Carter served as sales director for Celera Genomics, vice president of sales and marketing for Lark Technologies, and western regional manager for Applied Biosystems. Before joining ABI, he was a western regional manager with Polygen and a sales representative with PerkinElmer. He holds a BS in chemistry from Virginia Tech.
Larry Gold has been appointed to the scientific advisory board of Cambridge, Mass.-based Archemix. Archemix is developing aptamer-based therapeutics. Gold is currently the founder, board chairman, and chief scientific officer of SomaLogic. He developed the aptamer-based technology that is at the basis of both SomaLogic’s and Archemix’s platforms.
Prior to founding SomaLogic, Gold founded Nexagen, also for the development of aptamer technology, in the 1990s. Nexagen became Nexstar and then merged with Gilead Sciences in 1999.
“My joining Archemix’s scientific advisory board will further the close relationship SomaLogic and Archemix established last year, and will lead to an accelerated, joint development of aptamers for the diagnosis and treatment of disease,” Gold said in a statement.